Skip to main content

Infection

Retrospective study of 20 RA pts w/ resolved hepatitis B (HBcAb+; HBsAg neg). 16/20 were Rx w/ tocilizumab & 8/20 w/ tofacitinib (nearly all HBsAb+).

Dr. John Cush RheumNow ( View Tweet)

Aug 03, 2020

Fighting Hydroxychloroquine Misinformation

Aug 03, 2020

JAMA Internal Medicine has posted an Editor's note on the use of hydroxychloroquine for COVID-19; noting the sequence of dysfunction since the president promoted its use on March 21, 2020, when he said “What do you have to lose? I’ll say it again: What do you have to lose? Take it

Read Article

RheumNow Podcast - Top 13 Rheumatology Centers (7-31-20)

Jul 31, 2020

Dr. Jack Cush reviews the news and TOP 13 list of Best Rheumatology Hospitals.

Read Article

Colchicine Benefits COVID-19 Patients

Jul 30, 2020

A proof-of-concept study published in Annals of Rheumatic Disease suggests that colchicine significantly improves COVID-19 outcomes.

Efficacy and safety must be determined in controlled clinical trials.he outbreak of COVID-19 posed the issue of urgently identifying treatment strategies.

Read Article

Low Risk of COVID in Biologic Treated Rheum Patients

Jul 23, 2020

In an Annals of Rheumatic Disease report, Italian investigators performed consecutive testing for SARS-CoV-2 (IgM and IgG) between 25 March to 25 May 2020 and compared test results between rheumatic disease (RMD) patients and the general population. 



Their study included 295

Read Article

Rapid Loss of SARS-CoV-2 Antibodies in Mild Disease

Jul 23, 2020

According to a small, observational study out of UCLA published as correspondence in the NEJM on July 21, 2020, those with mild COVID-19 symptoms showed an approximate antibody half-life of 73 days.

COVID-19 infection was confirmed by PCR in 30 out of 34 study participants. The remaining four

Read Article

Higher Rates of SARS-CoV-2 Seropositivity in the USA

Jul 22, 2020

The number of reporting cases of COVID-19 infection tends to underestimate the true prevalence of infection as only the more severe cases (e.g.,acute respiratory syndrome) get tested or go to the hospital. JAMA Internal Medicine reports that a cross-sectional seroprevalence study from the U.S.

Read Article

Steroids and Tocilizumab in Cytokine Storm Syndrome

Jul 21, 2020

A recent study from the Netherlands has shown that patients with severe COVID-19-associated cytokine storm syndrome (CSS)  with high dose steroids and tocilizumab had a faster recovery, less need for invasive mechanical ventilation and fewer deaths when compared to CSS patients receiving

Read Article

RECOVERY Trial: Dexamethasone in COVID-19

Jul 20, 2020

Inflammatory events following infection with SARS-CoV-2 can often worsen the morbid or mortal outcomes with COVID, yet it has been unclear if glucocorticoids may modulate inflammation-mediated damage and lung injury.  The RECOVERY trial reports that dexamethasone (DEX) use lowered 28-day

Read Article
RheumNow Podcast is Up! Listen to Fauci! Watch it here>> https://t.co/dHq3fP85Ip or Listen to the Podcast>> https://t.co/LdHO7fKUCp

Dr. John Cush RheumNow ( View Tweet)

Jul 17, 2020

Characteristics Underlying Mortal COVID-19 Outcomes

Jul 17, 2020

From January 1, 2020–May 18, 2020, approximately 1.3 million cases of coronavirus disease 2019 (COVID-19) and 83,000 COVID-19–associated deaths were reported in the United States. MMWR reports that COVID-19 mortality is higher in persons with underlying medical conditions and in those aged ≥

Read Article

RheumNow Podcast – LTF – Listen to Fauci (7.17.20)

Jul 17, 2020

Dr. Jack Cush reviews the news, tweets and journal articles from the past week on RheumNow. Let's dig into this week's 14 highlights.

Read Article

Anti-Rheumatic Therapies for COVID-19 Infection

Jul 15, 2020

Since the onset of the COVID-19 pandemic numerous anti-rheumatic therapies have been proposed as being potentially beneficial. The mechanistic effects of these agents, either presumed antiviral, anti-inflammatory and anti-thrombotic effects, may benefit mitigate the damage seen with COVID-19

Read Article

Growing Risk of COVID Among Adolescents

Jul 13, 2020

The risk COVID-19 infection and mortality in the U.S. has been closely correlated with increasing age. However, recent data suggests that young adults (aged 18–25 years) have shown an increasing risk of COVID-19 infection since the pandemic began in March 2020.



Analysis of young

Read Article

Extrapulmonary Manifestations of COVID-19

Jul 13, 2020

A new article in Nature Medicine delineates how our understanding of COVID-19 infection has evolved over time, such that the infection outomes may be worsened by extrapulmonary manifestations; notably thrombotic, cardiac, renal, gastrointestinal hepatic, neurologic, and other complications.

Read Article

ICYMI: Protective Benefit of Colchicine in COVID-19 Infection

Jul 10, 2020

Colchicine has been advocated as a potential anti-inflammatory intervention in patients with the coronavirus 2 infection and clinical trials have been developed to assess its effect in early COVID-2 infection.  JAMA has published a randomized clinical trial showing that low dose colchicine had

Read Article

ICYMI: Preventing COVID - Masks, Meters and Eyewear

Jul 09, 2020

A Lancet systematic review and meta-analysis provides the basis for physical distancing and the value of making as measures to prevent infection with coronavirus 2 (SARS-CoV-2) or COVID-19.

The analysis included 172 observational studies, no randomised controlled trials and 44 relevant

Read Article

ICYMI: COVID-19 and Thrombotic Complications

Jul 08, 2020

Severe and fatal outcomes with coronavirus infection are often the result of the downstream damage that follows the viral infection. Rising high on the list of complications are the hematologic and vascular complications seen in severely affected patients, so much so that many centers are

Read Article

ICYMI: The Nine Lives of Hydroxychloroquine (Updated)

Hydroxychloroquine is one of many medications frequently used in rheumatology practice. Its remarkable versatility is attested by its routine use in lupus, in patients with an autoimmune coagulopathy, in patients with rheumatoid arthritis, as well as in those with a low-level inflammatory

Read Article

ICYMI: Outcomes of Critically-Ill COVID Patients in NYC

Jul 06, 2020

Lancet has reported COVID outcomes from NewYork-Presbyterian hospitals in NYC during March 2020 showing high rates of hospitalization, ICU admission, mechanical ventilation and death. 

A prospective observational cohort study 2 2 NYC hospitals from March 2 to April 1, 2020, looking at

Read Article

COVID's Multisystem Inflammatory Syndrome in Children

Jun 30, 2020

Two recent reports further characterize the newly described, Kawasaki-like,  syndrome affecting children with COVID-19 infections.

The NEJM describes the childhood syndrome as having Kawasaki’s disease, fever, toxic shock syndrome, acute abdominal conditions, and encephalopathy; hence the label

Read Article

Tocilizumab May Benefit COVID-19 Pneumonia

Jun 29, 2020

A retrospective, observational study published in Lancet Rheumatology has shown that tocilizumab (TCZ) may reduce the risk of death or the need for mechanical ventilation in severe COVID-19 pneumonia. This observational study included adults, with severe COVID-19 pneumonia, who were hospitalized

Read Article

RheumNow Podcast – Lupus Mortality Declines, But… (6.26.20)

Jun 26, 2020

Dr Jack Cush reviews the news and journal articles from the past week on RheumNow.com

Read Article

Protective Benefit of Colchicine in COVID-19 Infection

Jun 26, 2020

Colchicine has been advocated as a potential anti-inflammatory intervention in patients with the coronavirus 2 infection and clinical trials have been developed to assess its effect in early COVID-2 infection.  JAMA has published a randomized clinical trial showing that low dose colchicine had

Read Article

Hydroxychloroquine Fails as Postexposure Prophylaxis for Covid-19

Jun 22, 2020

Add this to the list of hydroxychloroquine (HCQ) letdowns in managing COVID-19 treatment or risk - prophylaxis with HCQ fails to prevent COVID-19 infection in those exposed to the SARS-CoV-2 virus. 

NEJM has reported a prospective, randomized, double-blind, placebo-controlled trial from the US

Read Article
×